Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Rubella Treatment Market size is projected to witness around 6.4% CAGR during the forecast period i.e., between 2025-2037.
The growth of the market can be largely attributed to the growing number of cases of rubella that results from high transmission ability of togavirus via air. Along with this, launch of several government initiatives associated with research and development of sophisticated diagnostic techniques, especially in emerging economies such as China and India, is expected to offer abundant opportunities for market growth in the near future. Furthermore, high risk of major complications in rubella infected pregnant women, and escalating government initiatives to include rubella vaccinations in national health programs, targeted mainly towards children and young adults, are also significant factors projected to augment the growth of the rubella treatment market in the upcoming years. According to the World Health Organization, 168 out of 194 countries introduced rubella vaccines in their health programs and the global coverage was about 69 percent as of December 2018. 14,621 cases of the disease were reported in 151 countries that same year.
Rubella Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Growing Incidences of Rubella Occurring from Togavirus via Air Worldwide
- Government Initiatives About Research and Development of Sophisticated Diagnostic Techniques
Challenges
- Side Effects Associated with Rubella Vaccination
Rubella Treatment Segmentation
The market is segmented by drug type into analgesic, nonsteroidal anti-inflammatory drugs, and others, out of which, the analgesic segment is anticipated to hold the largest share in the global rubella treatment market. This can be accounted to the high demand for analgesics across the globe owing to their ability to effectively reduce fever and relieve several kinds of mild to moderate pain. Additionally, on the basis of route of administration, the segment for oral route is predicted to grab the most significant share during the forecast period, which can be credited to its advantages, including patient compliance, non-invasiveness, and convenience of drug administration. Apart from these, most of the medicines for managing the symptoms of rubella are administered via oral route, which is also assessed to boost the segment’s growth in the future.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Type |
|
|
By Route of Administration |
|
|
By End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportRubella Treatment Industry - Regional Synopsis
On the basis of geographical analysis, the global rubella treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. North America industry is anticipated to account for largest revenue share by 2037, on account of growing levels of awareness about rubella, high healthcare spending, and rising number of drug manufacturing facilities in the region. The Centers for Medicare and Medicaid Services stated that in 2019, the healthcare expenditure in the United States reached a value of USD 11,582 per person in 2019. It accounted for 17.7 percent of the nation’s GDP that same year.
In addition, Europe is anticipated to be the second largest shareholder in the market during the forecast period owing to stringent regulatory framework and government guidelines regarding the health of mother and child. Moreover, the rubella treatment market in Asia Pacific is expected to witness noteworthy growth by the end of 2030, which can be credited to the increasing government initiatives to develop novel vaccines and therapies, and relatively low cost of drug production in the region.
Companies Dominating the Rubella Treatment Landscape
- Bayer AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- GlaxoSmithKline PLC
- Reckitt Benckiser Group plc
- Endo International plc
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
In the News
-
August 2021- GlaxoSmithKline announced that it has submitted a license application to the U.S Food and Drug Administration for PRIORIX, which is targeted for immunization against measles, mumps and rubella (MMR).
-
July 2019- Measles outbreak in the United States helped in boosting the sales of Merck’s vaccine by 58 percent in the second quarter of the year.
Author Credits: Radhika Pawar
- Report ID: 3621
- Published Date: Dec 26, 2024
- Report Format: PDF, PPT
